Mounjaro (for type II diabetes) and Zepbound (for obesity) — remains strong. Despite being on the market for less than three ...

Eli Lilly and Company’s LLY stock has declined 15.7% in the past year. The first-quarter earnings miss, guidance cut and some ...

JPMorgan said Eli Lilly is enrolling about 500,000 new obesity drug patients per month, and maintains more than 60% share in ...

Ricks said Eli Lilly had yet to begin what the company calls "demand-stimulating activities," or advertising and promoting, for Zepbound. The drugmaker will start those efforts in November, he said.

Pharmaceutical company Eli Lilly warning in an open letter on Thursday about the dangers of fake and compounded versions of its diabetes and weight loss medications Mounjaro and Zepbound.

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.

The reason for the disappointing sales, according to the company, is not an issue of demand or supply. During an earnings call Wednesday, Eli Lilly instead blamed it on drug wholesalers cutting ...

Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from ...